These findings, supported by preclinical research showing enhanced receptor internalisation and trastuzumab deruxtecan intracellular uptake in activating HER2 mutations, confirm the heightened activity of trastuzumab deruxtecan in HER2-mutant versus HER2-overexpressing NSCLC [49]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.